Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Conditions
- Aggressive Non-Hodgkin Lymphoma
- Blasts Under 5 Percent of Bone Marrow Nucleated Cells
- Chronic Lymphocytic Leukemia
- Loss of Chromosome 17p
- Myelodysplastic/Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
- Prolymphocytic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Aggressive Adult Non-Hodgkin Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Plasma Cell Myeloma
- Recurrent Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia
Interventions
- DRUG: Atorvastatin Calcium
- DRUG: Cyclosporine
- DRUG: Fludarabine Phosphate
- OTHER: Laboratory Biomarker Analysis
- DRUG: Mycophenolate Mofetil
- PROCEDURE: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- PROCEDURE: Peripheral Blood Stem Cell Transplantation
- RADIATION: Total-Body Irradiation
Sponsor
Fred Hutchinson Cancer Center
Collaborators
- [object Object]
- [object Object]